Syngene International (SYNGENE) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue from operations was ₹7,897 million, down 2% year-over-year, with operating EBITDA margin declining and net profit after exceptional items at ₹757 million, down 19% year-over-year.

• Dedicated Centers and Biologics Manufacturing Services showed steady growth, while Discovery Services were impacted by US biotech funding challenges.

• Over 400 active clients, including 14 of the top 20 pharma companies, and a workforce of 8,146 with 5,656 scientists.

• Leading indicators such as RFP value increased nearly 50% year-over-year, and multiple pilot projects in discovery services are underway.

• Introduced a new protein production platform, reducing development timelines for biologics and enabling faster patient access.

Financial highlights

• Q1 FY25 revenue from operations was ₹7,897 million, down 2% year-over-year and 14% sequentially from Q4 FY24.

• Operating EBITDA margin declined to 22%-23.3% from 26%-28.3% last year, due to higher costs and revenue mix.

• PAT after exceptional items was ₹757 million, down 19% year-over-year; PAT before exceptionals was ₹545 million, down 42% year-over-year.

• Net cash stood at ₹8,999 million as of June 30, 2024, similar to March 2024.

• Exceptional income of ₹320 million from a past insurance claim was received.

Outlook and guidance

• Full-year guidance remains unchanged, with expectations of improved business growth and revenue momentum in H2.

• EBITDA margin for the full year is expected in the high 20s, similar to last year, with sequential improvement as revenue grows.

• PAT growth for the full year is expected to be in single digits.

• The company has expanded into manufacturing, with revised inventory provisioning and depreciation policies expected to impact future costs.